Long-acting muscarinic antagonist (LAMA) monotherapy is recommended as first-line therapy for chronic obstructive pulmonary disease (COPD) per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups B, C, and D.
The first LAMA to be approved for COPD was tiotropium bromide. It is administered once daily due to its long duration of action. At first, this medication was delivered by a dry-powder inhaler (DPI) in the form of an inhalation powder. Now, it is available as an inhalation spray delivered via a soft mist inhaler (SMI). The SMI minimizes the necessity for strong inspiratory airflow, which is an issue with DPIs.
Short- and long-term clinical trials suggest that tiotropium bromide is safe and effective, and when compared with placebo/active comparators, improves lung function, health-related quality of life, and exercise endurance, as well as decreasing dyspnea, lung hyperinflation, exacerbations, and need for rescue medication compared.
Discussion questions: Which of your patients best respond to tiotropium bromide? How has treatment improved with the introduction of inhalation spray delivered by SMI?
-
Darin Skaudis, Physician3yrTiotropium as 1st line for patients with mild COPD and add LABA for moderate to severe COPD patients.
-
Sanjay Chavda, GEETA S CHAVDA MD PLLC3yrIt works well as a first line treatment for mild copd. Use with LABA for moderate copd
